Nearshoring is re-engineering supply chains. Learn why companies shift manufacturing closer to home for resilience by 2026.
·
·
7 min read
Beyond Lp(a): See how CRISPR and AI are shaping future heart medicine. New treatments target inflammation, genes, and personalized care by 2026.
·
·
4 min read
New heart drug discovery faced challenges. See 5 ways AI and organoids are speeding up R&D, impacting patients like Dr. Sharma's father.
·
·
9 min read
How did Coach Lombardi rebuild UNC football's offense? Learn his 5 key strategies, from player adaptation to advanced analytics like EPA data.
·
·
7 min read
Novartis's Lp(a) drug failure leaves 80% undiagnosed. What went wrong, and what new treatments are on the horizon for 2026?
·
·
6 min read
Is WHO's Ebola strategy failing? Learn why community trust and local control are missing, hindering 90% vaccine uptake.
·
·
6 min read
Pelacarsen failed its 2025 trial. Does this end Lp(a) drug research for heart disease? See why new siRNA drugs offer hope for high Lp(a).
·
·
7 min read
One in five people have high Lp(a), a heart disease risk. New drugs arriving by 2028 offer 50-80% reductions, changing preventative cardiology.
·
·
8 min read
Pelacarsen's 2026 trial failed to reduce heart events. What does this mean for Lp(a) drugs and future pharma development?
·
·
7 min read
Why are new heart drug costs hitting $1.5B by 2026? Learn about low clinical trial success, AI's role, and evolving FDA pathways.
·
·
7 min read